---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125435"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:10:51.661031+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Terns Pharma Q3 net loss $21.9M; cash $372.8M; TERN-701 data Dec 2024, TERN-601 Phase 2 start 2Q25

## Summary
- Net loss of $21.9M ($0.28/share) vs $29.8M loss ($0.42) in Q3 2023; R&D $15.2M, G&A $9.8M.
- Cash, equivalents and marketable securities $372.8M (incl. $172.7M equity raise in Sep) providing runway into 2028.
- Interim Phase 1 CARDINAL data for TERN-701 (allosteric BCR-ABL TKI in CML) expected early December 2024.
- Phase 2 trial for TERN-601 (oral GLP-1R agonist for obesity) to start early 2Q25; initial 12-week data in 2H25.

## SEC filing metadata
- accession: 0000950170-24-125435
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017024125435/0000950170-24-125435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017024125435/tern-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125435
- JSON: https://secwatch.observer/filing/0000950170-24-125435.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.